

The Secretary

Date: August 13, 2013

**Bangalore Stock Exchange Ltd.**

Stock Exchange Tower  
51, 1<sup>st</sup> Cross, J C Road  
Bangalore 560 027

**Bombay Stock Exchange Limited**

Corporate Relationship Dept.,  
P J Towers, Dalal Street, Fort,  
Mumbai 400 001

**National Stock Exchange of India Ltd.**

Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1, G Block,  
Bandra - Kurla Complex,  
Mumbai 450 051

Dear Sir(s),

**Sub: Un- audited Financial Results of the Company / Limited Review Report**

**Ref: Scrip Code - Bgse: ASTRAZEN /BSE: 506820 / NSE: ASTRAZEN EQ**

Please find attached Un-audited Financial Results for the first quarter ended June 30, 2013, which have been approved by the Board of Directors of the Company at its meeting held today, the 13<sup>th</sup> day of August, 2013.

The Limited Review Report dated August 13, 2013 issued by the Statutory Auditors in respect of the aforesaid Unaudited Financial Results is also attached.

Kindly take the same on record.

Thanking you,

For AstraZeneca Pharma India Limited

  
Pawan Singhal  
Vice President- Legal & Company Secretary

Financial results for the quarter ended 30 June 2013

Rs in lakhs (except for number of shares)

Part I		Statement of unaudited results for the quarter ended 30 June 2013			
SI No.	Particulars	3 months ended 30/06/2013	3 months ended 31/03/2013	3 months ended 30/06/2012	Previous year ended 31/03/2013
		(Unaudited)	(Audited) <sup>2</sup>	(Unaudited)	(Audited)
1	<b>Income from operations</b>				
	a) Net sales/ income from operations (net of excise duty)	12,513.72	9,485.13	9,126.08	39,025.42
	b) Other operating income	6.54	6.52	2.79	16.68
	<b>Total income from operations (net)</b>	<b>12,520.26</b>	<b>9,491.65</b>	<b>9,128.87</b>	<b>39,042.10</b>
2	<b>Expenses</b>				
	(a) Cost of materials consumed	2,173.50	1,454.65	715.85	4,497.53
	(b) Purchase of stock-in-trade	1,478.51	3,039.64	2,623.54	11,163.77
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	681.71	(1,383.90)	452.24	(347.91)
	(d) Employee benefits expense	3,396.94	3,681.98	3,339.55	14,846.02
	(e) Depreciation and amortisation expense	177.59	548.36	175.14	1,227.82
	(f) Other expenses	4,722.53	4,075.66	3,924.42	15,728.17
	<b>Total expenses</b>	<b>12,630.78</b>	<b>11,416.39</b>	<b>11,230.74</b>	<b>47,115.40</b>
3	<b>Profit/ (loss) from operations before other income, finance costs and exceptional items (1-2)</b>	<b>(110.52)</b>	<b>(1,924.74)</b>	<b>(2,101.87)</b>	<b>(8,073.30)</b>
4	Other income	287.36	67.21	783.53	1,046.29
5	<b>Profit/ (loss) from ordinary activities before finance costs and exceptional items (3+4)</b>	<b>176.84</b>	<b>(1,857.53)</b>	<b>(1,318.34)</b>	<b>(7,027.01)</b>
6	Finance costs	-	-	-	-
7	<b>Profit/ (loss) from ordinary activities after finance costs but before exceptional items (5-6)</b>	<b>176.84</b>	<b>(1,857.53)</b>	<b>(1,318.34)</b>	<b>(7,027.01)</b>
8	Exceptional items	-	-	-	-
9	<b>Profit/ (loss) from ordinary activities before tax (7+8)</b>	<b>176.84</b>	<b>(1,857.53)</b>	<b>(1,318.34)</b>	<b>(7,027.01)</b>
10	Tax expense	-	-	(503.74)	1,926.23
11	<b>Net profit/(loss) from ordinary activities after tax (9-10)</b>	<b>176.84</b>	<b>(1,857.53)</b>	<b>(814.60)</b>	<b>(8,953.24)</b>
12	Extraordinary Item	-	-	-	-
13	<b>Net profit/(loss) for the period (11-12)</b>	<b>176.84</b>	<b>(1,857.53)</b>	<b>(814.60)</b>	<b>(8,953.24)</b>
14	<b>Paid-up equity share capital</b> (Face value of Rs 2 per equity share)	<b>500.00</b>	<b>500.00</b>	<b>500.00</b>	<b>500.00</b>
15	<b>Reserves excluding revaluation reserves as per the balance sheet of previous accounting year</b>				<b>9,475.29</b>
16	<b>Basic and diluted earnings (Rs) per share [not annualised]</b>	<b>0.71</b>	<b>(7.43)</b>	<b>(3.26)</b>	<b>(35.81)</b>


Part II		Select information for the quarter ended 30 June 2013			
<b>A</b>	<b>Particulars of shareholding</b>				
1	<b>Public shareholding</b>				
	- Number of shares	6,250,000	2,500,050	2,500,050	2,500,050
	- Percentage of shareholding	25.0%	10.0002%	10.0002%	10.0002%
2	<b>Promoters and promoter group shareholding</b>				
	<b>a) Pledged/Encumbered</b>				
	- Number of shares	-	-	-	-
	- Percentage of shares ( as a % of the total shareholding of promoter and promoter group)	-	-	-	-
	- Percentage of shares ( as a % of the total share capital of the Company)	-	-	-	-
	<b>b) Non-encumbered</b>				
	- Number of shares	18,750,000	22,499,950	22,499,950	22,499,950
	- Percentage of shares ( as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%
	- Percentage of shares ( as a % of the total share capital of the Company)	75.0%	89.9998%	89.9998%	89.9998%

B.	Particulars	3 months ended 30/06/2013
	<b>Investor complaints</b>	
	Pending at the beginning of the quarter	Nil
	Received during the quarter	3
	Disposed of during the quarter	3
	Remaining unresolved at the end of the quarter	Nil

Notes:

- The above statement of financial results was reviewed by the Audit Committee and having been recommended for approval, was approved by the Board of Directors of the Company at their meeting held on 13 August 2013.
- Figures of the preceding 3 months ended 31 March 2013 are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. Also the figures upto the end of the third quarter were only reviewed and not subjected to audit.
- The Company's sole reportable business segment is - 'Healthcare'. The other segments are not material and are hence disclosed as 'Others'. Others comprise service income pertaining to clinical trials and co-promotion activities.
- Other income for the quarter ended 30 June 2012 includes an amount of Rs 693.49 lakhs towards compensation receivable for factory land acquired by National Highway Authority of India during the financial year 2011-12.
- The Company has entered into a subvention agreement dated 7 May 2013 with AstraZeneca Pharmaceuticals AB Sweden ("promoter company") wherein to assist the Company in its efforts to establish/grow its presence in the Indian market, the promoter company has voluntarily decided to provide non repayable financial grant. Accordingly, the Company has received Rs 2,103.15 lakhs during the quarter ended 30 June 2013 as financial grant. The amount received has been accounted for under liabilities as "Amount received under the subvention agreement" in line with accounting practice and would be utilised as per the terms of the agreement for recoupment of losses, if any, incurred by the Company in the subsequent periods.
- The Company has filed applications seeking approval of the Central Government to the appointment of Mr Sanjay Murdeshwar (as Managing Director on 2 May 2013) and Mr Robert Ian Haxton (as Whole Time Director). The applications are pending before the Central Government.
- In view of absence of profits for the year ended 31 March 2013, the approval of shareholders by a special resolution pursuant to the applicable provision of Schedule XIII of the Companies Act, 1956 for remuneration aggregating Rs 23 million paid to Mr Anandh Balasundram, former Managing Director, Ms Ruby Lau, former Whole Time Director and Mr Robert Ian Haxton, Whole Time Director for the year ended 31 March 2013 is being sought at the ensuing Annual General Meeting.
- In view of the inadequacy of profit during the current quarter, the remuneration to Mr Sanjay Murdeshwar and Mr Robert Ian Haxton is in accordance with the approval of the Board of Directors and the Remuneration Committee. The requisite approval of the shareholders is being sought at the ensuing Annual General Meeting.
- The above statement of financial results have been reviewed by the statutory auditors. The statutory auditors have issued an unqualified review report. The review report has been filed with the stock exchange and is also available on the company's website.

By Order of the Board of Directors  
For AstraZeneca Pharma India Limited

  
Sanjay Murdeshwar  
Managing Director

Segment wise revenue, results and capital employed

Sl.no	Particulars	(Rs in lakhs)			
		3 months ended 30/06/2013 (Unaudited)	3 months ended 31/03/2013 (Audited) <sup>2</sup>	3 months ended 30/06/2012 (Unaudited)	Previous year ended 31/03/2013 (Audited)
1	<b>Segment revenue</b>				
	(a) Healthcare	11,456.20	8,535.62	8,327.42	35,586.81
	(b) Others	1,064.06	956.03	801.45	3,455.29
	<b>Total</b>	<b>12,520.26</b>	<b>9,491.65</b>	<b>9,128.87</b>	<b>39,042.10</b>
	Less: Inter-segment revenue	-	-	-	-
	<b>Net income from operations</b>	<b>12,520.26</b>	<b>9,491.65</b>	<b>9,128.87</b>	<b>39,042.10</b>
2	<b>Segment results</b>				
	Profit/(loss) before tax and interest				
	(a) Healthcare	(335.00)	(2,089.94)	(2,078.25)	(8,477.84)
	(b) Others	224.48	165.20	(23.62)	404.54
<b>Total</b>	<b>(110.52)</b>	<b>(1,924.74)</b>	<b>(2,101.87)</b>	<b>(8,073.30)</b>	
	Add: Other income	287.36	67.21	783.53	1,046.29
	Less: Interest	-	-	-	-
	<b>Total profit/(loss) before tax</b>	<b>176.84</b>	<b>(1,857.53)</b>	<b>(1,318.34)</b>	<b>(7,027.01)</b>
3	<b>Capital employed</b>				
	(a) Healthcare	6,993.77	6,929.46	13,056.25	6,929.46
	(b) Others	151.91	122.37	619.21	122.37
	(c) Unallocated	3,006.47	2,923.46	4,438.47	2,923.46
<b>Total</b>	<b>10,152.15</b>	<b>9,975.29</b>	<b>18,113.93</b>	<b>9,975.29</b>	

**Notes :**

- Certain assets and liabilities of the Healthcare segment are interchangeably used for other segments for limited purposes. Identification of such assets and liabilities is not feasible. Hence, such assets have not been allocated to any segment.
- Figures of the preceding 3 months ended 31 March 2013 are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. Also the figures upto the end of the third quarter were only reviewed and not subjected to audit.

